hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06328088 id: EC/12/23/2400 briefTitle: Vegetarian Versus Non Vegetarian Based Diet in the Recurrence of Hepatic Encephalopathy in Patients With Cirrhosis: An Open Label Pilot Study overallStatus: RECRUITING date: 2024-02-16 date: 2024-04-16 date: 2024-10-16 date: 2024-03-25 date: 2024-03-25 name: Sir Ganga Ram Hospital class: OTHER briefSummary: Earlier protein restriction was advocated in the treatment of HE but later this concept was refuted and increase protein intake was advocated in patients with HE. Diet in patients during an episode HE is also not known. It is advisable based on many case reports or case series that vegetable-based diet during the episode of HE is better than animal-based diet as it reduces ammonia level and other false neurotransmitters in brain and helps in early recovery of, HE . However, diet in patients who had recovered from an episode of, HE is not known and what type of protein (vegetarian or non-vegetarian) should be taken to prevent another episode of HE has never been evaluated. In India majority of the patients are vegetarian and patients with cirrhosis are malnourished and lack protein in their diet as per our previous published study conditions: Hepatic Encephalopathy studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 40 type: ESTIMATED name: Non vegetarian measure: Recurrence of overt hepatic encephalopathy measure: Hospitalization due to any cause sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Sir Ganga Ram Hospital status: RECRUITING city: Delhi zip: 110060 country: India name: Praveen Sharma, MD,DM role: CONTACT phone: 9810365151 lat: 28.65195 lon: 77.23149 hasResults: False
nctId: NCT06328075 id: AI-ATTR-ECHO id: 20211029191554 type: OTHER domain: registre général des traitements de l'APHP briefTitle: Artificial Intelligence to Assist the Echocardiographic Identification of Transthyretin Cardiac Amyloidosis acronym: AI-ATTR-ECHO overallStatus: RECRUITING date: 2022-01-01 date: 2025-01-01 date: 2026-01-01 date: 2024-03-25 date: 2024-03-25 name: Algalarrondo Vincent class: OTHER name: Bichat Hospital name: Bioquantis briefSummary: The goal of this study is to develop an algorithm using artificial intelligence (AI) to assist identification of potential ATTR-CM cases using routine transthoracic echocardiography.
This is a non interventional study. Participant' echocardiographies will be, after deidentification, used to train, valid and test the algorithm. conditions: Amyloid Cardiomyopathy conditions: Transthyretin Amyloid Cardiomyopathy conditions: Transthyretin Cardiac Amyloidosis studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: OTHER count: 15000 type: ESTIMATED name: non interventional study measure: Building and validating the diagnostic performance metrics curves of the AI algorithm to diagnose ATTR-CM : measure: Building and validating the diagnostic performance metrics of the AI algorithm to diagnose ATTR-CM : measure: Building and validating the diagnostic performance metrics of the AI algorithm to diagnose ATTRwt-CM : measure: Building and validating the diagnostic performance metrics of the AI algorithm to diagnose ATTRv-V122I-CM : measure: Building and validating the diagnostic performance metrics of the AI algorithm to diagnose ATTRv-CM : measure: Building and validating the diagnostic performance metrics of the AI algorithm to differentiate ATTR-CM from LV hypertrophy (LVH) : measure: Building and validating the diagnostic performance metrics curves of the AI algorithm to diagnose ATTRwt-CM : measure: Building and validating the diagnostic performance metrics curves of the AI algorithm to diagnose ATTRv-V122I-CM : measure: Building and validating the diagnostic performance metrics curves of the AI algorithm to diagnose ATTRv-CM : measure: Building and validating the diagnostic performance metrics curves of the AI algorithm to differentiate ATTR-CM from LV hypertrophy (LVH) : sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bichat status: RECRUITING city: Paris zip: 75018 country: France name: Vincent Algalarrondo, MD, PhD role: CONTACT phone: +33140257785 email: vincent.algalarrondo@aphp.fr name: Gregory Ducrocq, PD, PhD role: CONTACT email: gregory.ducrocq@aphp.fr lat: 48.85341 lon: 2.3488 hasResults: False
nctId: NCT06328062 id: TUH Mirogabalin TKA briefTitle: Comparing Efficiency of Mirogabalin and Pregabalin in Primary TKA overallStatus: RECRUITING date: 2024-04-01 date: 2025-05-31 date: 2025-05-31 date: 2024-03-25 date: 2024-03-25 name: Thammasat University Hospital class: OTHER briefSummary: The goal of this RCT is to compare efficacy between mirogabalin and pregabalin in pain reducing after unilateral primary total knee arthroplasty.
Participants will randomized to mirogabalin or pregabalin group and will take the drug for 6 weeks after TKA. Researchers will compare to pregabalin group to see pain and functional outcomes after TKA. conditions: Pain Postoperative conditions: Osteoarthritis conditions: Total Knee Arthroplasty studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 80 type: ESTIMATED name: Mirogabalin name: Pregabalin measure: Pain score measure: Morphine consumption measure: Range of motion measure: Knee society score measure: Knee injury and Osteoarthritis Outcome Score (KOOS) measure: Sedation score measure: Incidence of Somnolence and dizziness measure: Total hospital stay sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Thammasat University Hospital status: RECRUITING city: Khlong Luang state: Pathum Thani zip: 12120 country: Thailand name: Yot Tanariyakul, M.D. role: CONTACT phone: 6683930257 email: y.tanariyakul@gmail.com name: Yot Tanariyakul, M.D. role: PRINCIPAL_INVESTIGATOR name: Krit Boontanapibul, M.D. role: PRINCIPAL_INVESTIGATOR lat: 14.06467 lon: 100.64578 hasResults: False
nctId: NCT06328049 id: HSKY-033 briefTitle: A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC overallStatus: RECRUITING date: 2023-08-10 date: 2025-02-10 date: 2025-08-10 date: 2024-03-25 date: 2024-03-25 name: Taixing People's Hospital class: OTHER briefSummary: The aim of this study is to investigate the safety and efficacy of the prophylactic use of Trilaciclib in patients with non-small cell lung cancer (NSCLC) receiving platinum-based chemotherapy, so as to provide more evidence-based medical evidence for the optimal diagnosis and treatment strategy in this population. conditions: NSCLC studyType: INTERVENTIONAL phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 30 type: ESTIMATED name: Trilaciclib Injection measure: Incidence of febrile neutropenia (FN) measure: Incidence of Treatment-Emergent Adverse Events measure: Antibiotic Use rate measure: Number of medication delays measure: Number of chemotherapy dose reductions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Taixing People's Hospital status: RECRUITING city: Taixing state: Jiangsu zip: 225400 country: China name: liu C yang, M.D. role: CONTACT phone: 87656001 phoneExt: 0523 email: liuyctx@163.com lat: 32.16667 lon: 120.01361 hasResults: False
nctId: NCT06328036 id: NCI-2024-02185 id: NCI-2024-02185 type: REGISTRY domain: CTRP (Clinical Trial Reporting Program) id: 10640 type: OTHER domain: University of Pittsburgh Cancer Institute LAO id: 10640 type: OTHER domain: CTEP id: UM1CA186690 type: NIH link: https://reporter.nih.gov/quickSearch/UM1CA186690 briefTitle: Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma overallStatus: NOT_YET_RECRUITING date: 2024-06-21 date: 2025-07-01 date: 2025-07-01 date: 2024-03-25 date: 2024-03-25 name: National Cancer Institute (NCI) class: NIH briefSummary: This phase II trial compares the safety, side effects and effectiveness of atezolizumab with tiragolumab to atezolizumab alone in treating patients with glioblastoma that has come back after a period of improvement (recurrent). Glioblastoma is the most common primary brain cancer in adults and despite aggressive treatment, it is nearly always fatal. Currently, there are limited effective treatment options in patients that have recurrence. Immunotherapy has been shown to be effective in other types of cancer and may be an appealing potential treatment option for recurrent glioblastoma. Immunotherapy with monoclonal antibodies, such as atezolizumab and tiragolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Study doctors also want to learn if a tumor infiltrating T lymphocyte (TIL) response is helpful to determine the benefit of the combination of study drugs compared to the usual approach. TILs are a type of immune cell that has moved from the blood into a tumor. TILs can recognize and kill tumor cells. Giving atezolizumab with tiragolumab may be safe, tolerable and/or effective compared to atezolizumab alone in treating patients with recurrent glioblastoma. conditions: Recurrent Glioblastoma, IDH-Wildtype studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 52 type: ESTIMATED name: Atezolizumab name: Biospecimen Collection name: Magnetic Resonance Imaging name: Surgical Procedure name: Tiragolumab measure: Progression free survival (PFS) measure: Tumor infiltrating T lymphocyte density measure: Dose limiting toxicity measure: Incidence of adverse events measure: Objective response rate (ORR) measure: PFS6 measure: Overall survival measure: Tumor mutational burden (TMB) measure: Expression of immune checkpoint receptors and ligands measure: Tumor response signatures including for T-cells, interferon and cell cycle measure: T cell receptor (TCR) clonality and diversity measure: Tumor infiltrating T-cell, T-regs, and myeloid cells measure: TCR overlap and clonal expression measure: Peripheral blood mononuclear cell (PBMC) response signatures including for T-cells, interferon and cell cycle measure: TCR clonality by PBMC measure: TCR clonality measure: Trough concentrations in serum and concentrations in cerebrospinal fluid sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06328023 id: REC/MS-PT/01831 briefTitle: Impact of Concussion History on Sleep and Physical Performance in Contact Sports Athletes overallStatus: RECRUITING date: 2024-03-18 date: 2024-04-23 date: 2024-06-02 date: 2024-03-25 date: 2024-03-27 name: Riphah International University class: OTHER briefSummary: This study investigates the correlation between a history of concussions and its effects on both sleep patterns and physical performance among athletes engaged in contact sports. By examining the relationship between concussion history, sleep quality, and athletic performance, this research aims to provide insights into the potential long-term implications of concussions on the well-being and performance of athletes in contact sports conditions: Concussion, Mild conditions: Sleep conditions: Physical Performance studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 115 type: ESTIMATED name: SCOAT 6 to find association measure: Cantu Scale measure: Sport Concussion Office Assessment Tool 6 sex: ALL minimumAge: 18 Years maximumAge: 36 Years stdAges: ADULT facility: HAYATABAD Sports complex status: RECRUITING city: Peshawar state: Khyber Pakhtun Khawan zip: 24730 country: Pakistan name: Nadia Ishtiaq, MSOMPT role: CONTACT phone: 03486977541 email: Nadia.Ishtiaq@riphah.edu.pk name: Muhammad haroon, MSSPT* role: CONTACT phone: 03484644733 email: muhammad-haroon6528@zu.edu.pk name: Muhammad Haroon, MS*SPT role: PRINCIPAL_INVESTIGATOR lat: 34.008 lon: 71.57849 hasResults: False
nctId: NCT06328010 id: SIDDXAC02 briefTitle: An Observational Clinical Registry to Collect Safety and Efficacy Data on Wound Care in Medical Centers acronym: SIDDX overallStatus: ENROLLING_BY_INVITATION date: 2024-04-01 date: 2028-12-31 date: 2030-06-30 date: 2024-03-25 date: 2024-04-29 name: Siddhey LLC class: INDUSTRY briefSummary: Collect data on various wound treatments and their related wound healing process, in real life settings.
Analyze the safety and efficacy of wound treatments, including: advanced biological/synthetic grafts and standard of wound care treatments. conditions: Wounds and Injuries conditions: Burns conditions: Mohs Surgery conditions: Diabetic Foot Ulcer Mixed conditions: Venous Leg Ulcer conditions: Non-healing Wound conditions: Trauma Injury conditions: Injury and Wounds conditions: Degloving Injuries studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 5000 type: ESTIMATED name: Advanced Treatment Modalities for wound and injuries measure: Data collection of 5000 patients measure: Different types of wounds/injuries heal rate sex: ALL minimumAge: 21 Years maximumAge: 90 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Comprehensive Medicine city: Alpine state: California zip: 91901 country: United States lat: 32.83505 lon: -116.76641 facility: West Hills Hospital and Medical Centers Doctors Suites city: West Hills state: California zip: 91307 country: United States lat: 34.19731 lon: -118.64398 hasResults: False
nctId: NCT06327997 id: BZE2203-A-01 briefTitle: An Exploratory Study by Fast CAR T Cells overallStatus: RECRUITING date: 2024-03-07 date: 2027-03-06 date: 2027-12-31 date: 2024-03-25 date: 2024-03-25 name: Shanghai Cell Therapy Group Co.,Ltd class: INDUSTRY briefSummary: The main goal of this trial is to evaluate the safety and tolerability of CAR T cell therapy for advanced solid tumors with positive mesothelin and MUC1.Patients were screened, peripheral blood mononuclear cells (PBMC) were isolated from eligible patients, and cells were prepared. Pretreatment was performed within 5 days before infusion, and CAR T cells were infused on day 0 (the dose was determined according to the requirements of climbing/expansion). The safety intensive observation period was 28 days after infusion, and the clinical efficacy after infusion was evaluated on days 28-34. The follow-up observation and evaluation were carried out according to the follow-up visit point, and the follow-up period was 1 year. From the second year, the telephone follow-up period was entered. conditions: Solid Tumor studyType: INTERVENTIONAL phases: EARLY_PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Fast CAR T cells measure: Dose-limiting toxicity(DLT) measure: Maximum tolerated dose (MTD) measure: Objective response rate (ORR) measure: Progression-free survival (PFS) measure: Overall survival (OS) measure: Peak Plasma Concentration (Cmax) measure: AUC measure: Pharmacodynamics (PD) sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Shanghai Mengchao Cancer Hospital status: RECRUITING city: Shanghai state: Shanghai country: China name: Lou jinxing role: CONTACT lat: 31.22222 lon: 121.45806 hasResults: False
nctId: NCT06327984 id: 157354 briefTitle: Barts Sex-CAD Database overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2027-05 date: 2027-05 date: 2024-03-25 date: 2024-03-25 name: Queen Mary University of London class: OTHER briefSummary: There is a lack of understanding of how Coronary Artery Disease (CAD) - meaning the blocking or furring up of the arteries of the heart - starts and progresses in women. In both men and women, CAD is the most common cause of heart attacks, which occur when the blood supply in the heart is interrupted (these are also known medically as 'acute coronary syndromes').
Before the menopause women appear to be protected from CAD; however, after the menopause that protection is lost. Also, those women who do suffer a heart attack have twice the risk of further heart attacks compared to men despite having the same treatment that works well in men. Biological differences between men and women are probably playing an important role in the way CAD develops. However, due to a lack of research there is currently little understanding of how the female body works in this area.
In this study we wish to measure the 'markers' of inflammation in the blood of patients attending Barts Heart Centre with chest pain. We will also conduct questionnaires with these patients, to understand their hormone status and how parts of their medical history may be a contributory factor. For patients who have previously attended Barts Heart Centre will will contact them to conduct the questionnaire over the telephone only. We will combine this data with the data that is routinely collected during hospital admission. In this way we hope to understand whether inflammation together with hormone status plays an important role in CAD. Our hope is that through this research we will address an under researched area and find new ways of treating women and men with coronary artery disease. conditions: Coronary Artery Disease conditions: Myocardial Infarction conditions: Acute Coronary Syndrome conditions: Atherosclerosis conditions: Inflammation studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 6000 type: ESTIMATED measure: Mortality measure: Re-admission measure: MACE measure: Relationship with specific MI types measure: Relationship with inflammation sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06327971 id: 0000 briefTitle: Enhanced Outcome Prediction in Cutaneous Squamous Cell Carcinoma Using Deep-learning and Computational Histopathology overallStatus: ACTIVE_NOT_RECRUITING date: 2023-10-20 date: 2028-10 date: 2028-10 date: 2024-03-25 date: 2024-03-25 name: Queen Mary University of London class: OTHER briefSummary: Evaluate a deep-learning model trained on computational histopathology for predicting outcomes in cutaneous squamous cell carcinoma conditions: Squamous Cell Carcinoma of the Skin studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 300 type: ESTIMATED measure: Metastasis sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Barts Health NHS Trust city: London country: United Kingdom lat: 51.50853 lon: -0.12574 hasResults: False
nctId: NCT06327958 id: protocol Number: 2021/21 briefTitle: THE EFFECTS OF DIRECT AND INDIRECT LARYNGOSCOPY ON CORMACK-LEHANE AND POGO SCORES overallStatus: COMPLETED date: 2021-09-15 date: 2022-06-15 date: 2022-06-30 date: 2024-03-25 date: 2024-03-25 name: Zonguldak Bulent Ecevit University class: OTHER briefSummary: Direct laryngoscopy (DL) is a conventional and highly difficult method that is used in endotracheal intubation (ETI) training. Today, the usage of video-laryngoscopes (VLs) to teach airway management to inexperienced healthcare personnel is a prevalent practice. In ETI training, it is recommended to train students on simulators before allowing them direct access to patients. conditions: Being a 5th Year Student at the Faculty of Medicine conditions: No Previous Laryngoscopy Experience studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 130 type: ACTUAL name: Cormack-Lehane (C&L) name: POGO score measure: The percentage of glottic opening (POGO) scores in the airway management training of medical students. sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Zonguldak Bülent Ecevit University city: Zonguldak state: Kozlu zip: 67600 country: Turkey lat: 41.45139 lon: 31.79305 hasResults: False
nctId: NCT06327945 id: 22-00009 briefTitle: Transplanting Lungs From Uncontrolled Donation After Circulatory Death overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2027-06-30 date: 2028-06-30 date: 2024-03-25 date: 2024-03-25 name: NYU Langone Health class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: The study team developed an uncontrolled donation after circulatory death (uDCD) protocol that preserves lungs for just over 3 hours after death using positive end expiratory pressure (PEEP) and supplemental oxygen. The study will assess lung uDCD program safety by continuous review of operations/clinical records from each case activation and transplantation. Attrition outcomes include rates of initial and continued lung preservation, donation authorization, lung recovery, passing ex-vivo lung perfusion (EVLP) performance testing, and lung transplantation. Planned viability assessments also include macroscopic determination, radiology (X-ray), and fiber optic bronchoscopy before initiating EVLP. We expect \~50% of lungs assessed with EVLP will be transplanted to meet sustainability targets. Safety outcomes include the primary outcome, primary graft dysfunction (PGD) grade III at 72 hours, and secondarily survival one year after transplantation. conditions: Lung Transplantation studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: OTHER masking: NONE count: 24 type: ESTIMATED name: Lung uDCD Protocol measure: Incidence of Primary Graft Dysfunction (PDG) Grade III measure: Number of Participants who Required Normothermic Extracorporeal Membrane Oxygenation (nECMO) measure: Number of Participants who Required Normothermic Extracorporeal Membrane Oxygenation (nECMO) measure: Incidence of Re-Transplantation measure: Overall Survival measure: Overall Survival sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: NYU Langone Health city: New York state: New York zip: 10016 country: United States lat: 40.71427 lon: -74.00597 hasResults: False
nctId: NCT06327932 id: HIVEC(PRG) briefTitle: HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2026-03-31 date: 2028-03-31 date: 2024-03-25 date: 2024-03-25 name: Affiliated Cancer Hospital & Institute of Guangzhou Medical University class: OTHER briefSummary: The purpose of this study is to determine the efficacy and safety of Hyperthermic Intravesical Chemotherapy (HIVEC) with Gemcitabine (GEM) after Transurethral Resection of Bladder Tumors (TURBT) in the treatment of medium or high-risk group Non-Muscle-Invasive Bladder Cancer (NMIBC). conditions: Non-Muscle-Invasive Bladder Cancer studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 320 type: ESTIMATED name: TURBT name: HIVEC name: Intravesical Chemotherapy name: Gemcitabine measure: Recurrence rate measure: 1-year recurrence rate measure: Recurrence-free survival (RFS) rate measure: Time to treatment failure measure: Success rate of therapeutic operation measure: Quality of international prostate symptom score measure: Quality of bother of score sex: ALL minimumAge: 18 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False